Iovance Biotherapeutics, Inc. Common Stock Stock Prediction
AI-powered sentiment analysis and prediction trends for IOVA, updated each market day.
IOVA AI Sentiment
AI sees no strong directional signal for Iovance Biotherapeutics, Inc. Common Stock stock over the next 10 market days.
Prediction date: April 10, 2026
Subscribers see precise scores, buy/sell targets, and full analytics.
About Iovance Biotherapeutics, Inc. Common Stock
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. It operates in one segment, focusing on innovating, developing, and commercializing therapies using its autologous TIL cell therapies for patients with solid tumor cancers. Geographically, the company operates in United States and Rest of the World.
Sector
Exchange
Market Cap
$1,651,966,044
Cap Tier
Employees
975
Headquarters
SAN CARLOS, CA
Listed Since
May 26, 2010
Website
IOVA Sentiment Trend — Last 30 Predictions
Sentiment zones: Bullish · Neutral · Bearish
IOVA Volatility
Iovance Biotherapeutics, Inc. Common Stock has shown high price volatility over the last 5 trading days. High volatility means larger price swings — this can present both opportunity and risk for traders.
